Clinical trials: Stage II Rectosigmoid Cancer
Colorectal Cancer
Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
This study is designed primarily to establish efficacy and estimate resource utilization. The short-term hypothesis is that the dose of capecitabine (825 mg/m2 twice/day 5 days per week) during the course of radiation therapy is…
- Trial name
- NCT00216424
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- James A. Haley Veterans Administration Hospital
Ovarian Cancer, Ovarian Carcinoma
A Study of Intra-operative Imaging in Women With Ovarian Cancer
The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard…
- Trial name
- NCT04878094
- Testing
- Intravenous Indocyanine Green/ICG injection, PINPOINT endoscopic fluorescence imaging system, Endoscopy
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer Survivor, Stage I Rectosigmoid Cancer
Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors
This pilot clinical trial studies how well personalized dietary intervention works in managing bowel dysfunction and improving quality of life in stage I-III rectosigmoid cancer survivors.
- Conditions
- Cancer Survivor, Stage I Rectosigmoid Cancer, Stage II Rectosigmoid Cancer, Stage III Rectosigmoid Cancer
- Trial name
- NCT03063918
- Testing
- Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer, Rectosigmoid Cancer
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI will receive 6 cycles of neoadjuvant treatment with mFOLFOX6 (Arm A) vs. mFOLFOX6 + aflibercept (Arm B) followed by surgery.
- Trial name
- NCT03043729
- Testing
- Oxaliplatin, 5-FU, Leucovorin
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- AIO-Studien-gGmbH